Cathepsins (S and B) and their inhibitor Cystatin C in immune cells: Modulation by interferon-β and role played in cell migration

Journal of Neuroimmunology

Volumn 232, Issue 1-2, 2011, Pages 200-206

  Staun Ram, Elsebeth ^a   Miller, Ariel ^a,b  

^a TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

^b CARMEL MEDICAL CENTER   (Israel)

Author keywords

Autoimmunity; Biomarkers; Cathepsins; Immunomodulation; Interferon; Multiple sclerosis

Indexed keywords

BETA INTERFERON; CATHEPSIN B; CATHEPSIN S; CYSTATIN C; GAMMA INTERFERON;

ARTICLE; CELL MIGRATION; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY TEST; HUMAN; HUMAN CELL; IMMUNOCOMPETENT CELL; IMMUNOMODULATION; LEUKEMIA CELL LINE; MONOCYTE; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN SECRETION; T LYMPHOCYTE;

BLOTTING, WESTERN; CATHEPSIN B; CATHEPSINS; CELL MOVEMENT; CHEMOTAXIS, LEUKOCYTE; CYSTATIN C; HUMANS; INTERFERON-BETA; JURKAT CELLS; MONOCYTES; T-LYMPHOCYTES; U937 CELLS;

EID: 79952250111     PISSN: 01655728     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jneuroim.2010.10.015     Document Type: Article

References (57)

1. Abraham M., Shapiro S., Lahat N., Miller A. The role of IL-18 and IL-12 in the modulation of matrix metalloproteinases and their tissue inhibitors in monocytic cells. Int. Immunol. 2002, 14:1449-1457.
2. Abrahamson M., Barrett A.J., Salvesen G., Grubb A. Isolation of six cysteine proteinase inhibitors from human urine. Their physicochemical and enzyme kinetic properties and concentrations in biological fluids. J. Biol. Chem. 1986, 261:11282-11289.
3. Alter A., Duddy M., Hebert S., Biernacki K., Prat A., Antel J.P., Yong V.W., Nuttall R.K., Pennington C.J., Edwards D.R., Bar-Or A. Determinants of human B cell migration across brain endothelial cells. J. Immunol. 2003, 170:4497-4505.
4. Beck H., Schwarz G., Schroter C.J., Deeg M., Baier D., Stevanovic S., Weber E., Driessen C., Kalbacher H. Cathepsin S and an asparagine-specific endoprotease dominate the proteolytic processing of human myelin basic protein in vitro. Eur. J. Immunol. 2001, 31:3726-3736.
5. Bever C.T., Garver D.W. Increased cathepsin B activity in multiple sclerosis brain. J. Neurol. Sci. 1995, 131:71-73.
6. Bever C.T., Panitch H.S., Johnson K.P. Increased cathepsin B activity in peripheral blood mononuclear cells of multiple sclerosis patients. Neurology 1994, 44:745-748.
7. Biernacki K., Prat A., Blain M., Antel J.P. Regulation of Th1 and Th2 lymphocyte migration by human adult brain endothelial cells. J. Neuropathol. Exp. Neurol. 2001, 60:1127-1136.
8. Bleul C.C., Fuhlbrigge R.C., Casasnovas J.M., Aiuti A., Springer T.A. A highly efficacious lymphocyte chemoattractant, stromal cell-derived factor 1 (SDF-1). J. Exp. Med. 1996, 183(3):1101-1109.
9. Boz C., Ozmenoglu M., Velioglu S., Kilinc K., Orem A., Alioglu Z., Altunayoglu V. Matrix metalloproteinase-9 (MMP-9) and tissue inhibitor of matrix metalloproteinase (TIMP-1) in patients with relapsing-remitting multiple sclerosis treated with interferon beta. Clin. Neurol. Neurosurg. 2006, 108:124-128.
10. Bradley J.D., Whitaker J.N. Isolation and characterization of cathepsin B from bovine brain. Neurochem. Res. 1986, 11:851-867.
11. Brix K., Dunkhorst A., Mayer K., Jordans S. Cysteine cathepsins: cellular roadmap to different functions. Biochimie 2008, 90:194-207.
12. Buttmann M., Lorenz A., Weishaupt A., Rieckmann P. Atorvastatin partially prevents an inflammatory barrier breakdown of cultured human brain endothelial cells at a pharmacologically relevant concentration. J. Neurochem. 2007, 102:1001-1008.
13. Callahan M.K., Williams K.A., Kivisakk P., Pearce D., Stins M.F., Ransohoff R.M. CXCR3 marks CD4+ memory T lymphocytes that are competent to migrate across a human brain microvascular endothelial cell layer. J. Neuroimmunol. 2004, 153:150-157.
14. Cunningham S., Graham C., Hutchinson M., Droogan A., O'Rourke K., Patterson C., McDonnell G., Hawkins S., Vandenbroeck K. Pharmacogenomics of responsiveness to interferon IFN-beta treatment in multiple sclerosis: a genetic screen of 100 type I interferon-inducible genes. Clin. Pharmacol. Ther. 2005, 78:635-646.
15. Dressel A., Mirowska-Guzel D., Gerlach C., Weber F. Migration of T-cell subsets in multiple sclerosis and the effect of interferon-beta1a. Acta Neurol. Scand. 2007, 116:164-168.
16. Driessen C., Bryant R.A., Lennon-Dumenil A.M., Villadangos J.A., Bryant P.W., Shi G.P., Chapman H.A., Ploegh H.L. Cathepsin S controls the trafficking and maturation of MHC class II molecules in dendritic cells. J. Cell Biol. 1999, 147:775-790.
17. Fissolo N., Kraus M., Reich M., Ayturan M., Overkleeft H., Driessen C., Weissert R. Dual inhibition of proteasomal and lysosomal proteolysis ameliorates autoimmune central nervous system inflammation. Eur. J. Immunol. 2008, 38:2401-2411.
18. Flannery T., McQuaid S., McGoohan C., McConnell R.S., McGregor G., Mirakhur M., Hamilton P., Diamond J., Cran G., Walker B., Scott C., Martin L., Ellison D., Patel C., Nicholson C., Mendelow D., McCormick D., Johnston P.G. Cathepsin S expression: an independent prognostic factor in glioblastoma tumours-a pilot study. Int. J. Cancer 2006, 119:854-860.
19. Frlan R., Gobec S. Inhibitors of cathepsin B. Curr. Med. Chem. 2006, 13:2309-2327.
20. Galboiz Y., Shapiro S., Lahat N., Rawashdeh H., Miller A. Matrix metalloproteinases and their tissue inhibitors as markers of disease subtype and response to interferon-beta therapy in relapsing and secondary-progressive multiple sclerosis patients. Ann. Neurol. 2001, 50:443-451.
21. Gocheva V., Joyce J.A. Cysteine cathepsins and the cutting edge of cancer invasion. Cell Cycle 2007, 6:60-64.
22. Grossman I., Avidan N., Singer C., Goldstaub D., Hayardeny L., Eyal E., Ben-Asher E., Paperna T., Pe'er I., Lancet D., Beckmann J.S., Miller A. Pharmacogenetics of glatiramer acetate therapy for multiple sclerosis reveals drug-response markers. Pharmacogenet. Genomics 2007, 17:657-666.
23. Grzonka Z., Jankowska E., Kasprzykowski F., Kasprzykowska R., Lankiewicz L., Wiczk W., Wieczerzak E., Ciarkowski J., Drabik P., Janowski R., Kozak M., Jaskolski M., Grubb A. Structural studies of cysteine proteases and their inhibitors. Acta Biochim. Pol. 2001, 48:1-20.
24. Hansen T., Petrow P.K., Gaumann A., Keyszer G.M., Eysel P., Eckardt A., Brauer R., Kriegsmann J. Cathepsin B and its endogenous inhibitor cystatin C in rheumatoid arthritis synovium. J. Rheumatol. 2000, 27:859-865.
25. Hansson S.F., Simonsen A.H., Zetterberg H., Andersen O., Haghighi S., Fagerberg I., Andreasson U., Westman-Brinkmalm A., Wallin A., Ruetschi U., Blennow K. Cystatin C in cerebrospinal fluid and multiple sclerosis. Ann. Neurol. 2007, 62:193-196. discussion 205.
26. Hao H.P., Doh-Ura K., Nakanishi H. Impairment of microglial responses to facial nerve axotomy in cathepsin S-deficient mice. J. Neurosci. Res. 2007, 85:2196-2206.
27. Haorah J., Ramirez S.H., Schall K., Smith D., Pandya R., Persidsky Y. Oxidative stress activates protein tyrosine kinase and matrix metalloproteinases leading to blood-brain barrier dysfunction. J. Neurochem. 2007, 101:566-576.
28. Haves Zburof D.P.T., Gour-Lavie A., Mandel I., Glass-Marmor L., Miller A. Cathepsins and their endogenous inhibitors cystatins in multiple sclerosis. World congress on treatment and research in Multiple Sclerosis, (ECTRIMS), Montreal, Canada.(Abstract) 2008.
29. Honey K., Rudensky A.Y. Lysosomal cysteine proteases regulate antigen presentation. Nat. Rev. Immunol. 2003, 3:472-482.
30. Ifergan I., Kebir H., Bernard M., Wosik K., Dodelet-Devillers A., Cayrol R., Arbour N., Prat A. The blood-brain barrier induces differentiation of migrating monocytes into Th17-polarizing dendritic cells. Brain 2008, 131:785-799.
31. Irie O., Kosaka T., Kishida M., Sakaki J., Masuya K., Konishi K., Yokokawa F., Ehara T., Iwasaki A., Iwaki Y., Hitomi Y., Toyao A., Gunji H., Teno N., Iwasaki G., Hirao H., Kanazawa T., Tanabe K., Hiestand P.C., Malcangio M., Fox A.J., Bevan S.J., Yaqoob M., Culshaw A.J., Hart T.W., Hallett A. Overcoming hERG issues for brain-penetrating cathepsin S inhibitors: 2-cyanopyrimidines. Part 2. Bioorg. Med. Chem. Lett. 2008, 18:5280-5284.
32. Jevnikar Z., Obermajer N., Bogyo M., Kos J. The role of cathepsin X in the migration and invasiveness of T lymphocytes. J. Cell Sci. 2008, 121:2652-2661.
33. Liu K.K., Dorovini-Zis K. Regulation of CXCL12 and CXCR4 expression by human brain endothelial cells and their role in CD4+ and CD8+ T cell adhesion and transendothelial migration. J. Neuroimmunol. 2009, 215(1-2):49-64.
34. Malik M., Chen Y.Y., Kienzle M.F., Tomkowicz B.E., Collman R.G., Ptasznik A. Monocyte migration and LFA-1-mediated attachment to brain microvascular endothelia is regulated by SDF-1 alpha through Lyn kinase. J. Immunol. 2008, 181(7):4632-4637.
35. Mathews S.A., Kurien B.T., Scofield R.H. Oral manifestations of Sjogren's syndrome. J. Dent. Res. 2008, 87:308-318.
36. Nagai A., Murakawa Y., Terashima M., Shimode K., Umegae N., Takeuchi H., Kobayashi S. Cystatin C and cathepsin B in CSF from patients with inflammatory neurologic diseases. Neurology 2000, 55:1828-1832.
37. Podgorski I., Sloane B.F. Cathepsin B and its role(s) in cancer progression. Biochem. Soc. Symp. 2003, 263-276.
38. Prat A., Al-Asmi A., Duquette P., Antel J.P. Lymphocyte migration and multiple sclerosis: relation with disease course and therapy. Ann. Neurol. 1999, 46:253-256.
39. Prat A., Biernacki K., Lavoie J.F., Poirier J., Duquette P., Antel J.P. Migration of multiple sclerosis lymphocytes through brain endothelium. Arch. Neurol. 2002, 59:391-397.
40. Prat A., Biernacki K., Antel J.P. Th1 and Th2 lymphocyte migration across the human BBB is specifically regulated by interferon beta and copolymer-1. J. Autoimmun. 2005, 24:119-124.
41. Premzl A., Zavasnik-Bergant V., Turk V., Kos J. Intracellular and extracellular cathepsin B facilitate invasion of MCF-10A neoT cells through reconstituted extracellular matrix in vitro. Exp. Cell Res. 2003, 283:206-214.
42. Ransohoff R.M. Natalizumab for multiple sclerosis. N Engl J. Med. 2007, 356:2622-2629.
43. Saegusa K., Ishimaru N., Yanagi K., Arakaki R., Ogawa K., Saito I., Katunuma N., Hayashi Y. Cathepsin S inhibitor prevents autoantigen presentation and autoimmunity. J. Clin. Invest. 2002, 110:361-369.
44. Seguin R., Biernacki K., Rotondo R.L., Prat A., Antel J.P. Regulation and functional effects of monocyte migration across human brain-derived endothelial cells. J. Neuropathol. Exp. Neurol. 2003, 62:412-419.
45. Sellebjerg F., Sorensen T.L. Chemokines and matrix metalloproteinase-9 in leukocyte recruitment to the central nervous system. Brain Res. Bull. 2003, 61:347-355.
46. Silwedel C., Forster C. Differential susceptibility of cerebral and cerebellar murine brain microvascular endothelial cells to loss of barrier properties in response to inflammatory stimuli. J. Neuroimmunol. 2006, 179:37-45.
47. Sohar N., Sohar I., Hammer H. Lysosomal enzyme activities: new potential markers for Sjogren's syndrome. Clin. Biochem. 2005, 38:1120-1126.
48. Sokol J.P., Neil J.R., Schiemann B.J., Schiemann W.P. The use of cystatin C to inhibit epithelial-mesenchymal transition and morphological transformation stimulated by transforming growth factor-beta. Breast Cancer Res. 2005, 7:R844-R853.
49. Stins M.F., Gilles F., Kim K.S. Selective expression of adhesion molecules on human brain microvascular endothelial cells. J. Neuroimmunol. 1997, 76:81-90.
50. Stins M.F., Nemani P.V., Wass C., Kim K.S. Escherichia coli binding to and invasion of brain microvascular endothelial cells derived from humans and rats of different ages. Infect. Immun. 1999, 67:5522-5525.
51. Stins M.F., Badger J., Sik Kim K. Bacterial invasion and transcytosis in transfected human brain microvascular endothelial cells. Microb. Pathog. 2001, 30:19-28.
52. Tripathi A.K., Sullivan D.J., Stins M.F. Plasmodium falciparum-infected erythrocytes increase intercellular adhesion molecule 1 expression on brain endothelium through NF-kappaB. Infect. Immun. 2006, 74:3262-3270.
53. Tripathi A.K., Sullivan D.J., Stins M.F. Plasmodium falciparum-infected erythrocytes decrease the integrity of human blood-brain barrier endothelial cell monolayers. J. Infect. Dis. 2007, 195:942-950.
54. Yan S., Sloane B.F. Molecular regulation of human cathepsin B: implication in pathologies. Biol. Chem. 2003, 384:845-854.
55. Yang H., Kala M., Scott B.G., Goluszko E., Chapman H.A., Christadoss P. Cathepsin S is required for murine autoimmune myasthenia gravis pathogenesis. J. Immunol. 2005, 174:1729-1737.
56. Yang Y., Liu S., Qin Z., Cui Y., Qin Y., Bai S. Alteration of cystatin C levels in cerebrospinal fluid of patients with Guillain-Barre Syndrome by a proteomical approach. Mol. Biol. Rep. 2009, 36:677-682.
57. Yasuda Y., Kaleta J., Bromme D. The role of cathepsins in osteoporosis and arthritis: rationale for the design of new therapeutics. Adv. Drug Deliv. Rev. 2005, 57:973-993.